Abstract
Overall survival (OS) of phase 1 (P1) cancer patients (pts) is difficult to predict. The Royal Marsden Hospital (RMH) prognostic score (which incorporates serum albumin, LDH, and no. of metastatic sites) and neutrophil-lymphocyte ratio (NLR) have been validated to predict OS in P1 trial pts in the Western population but not Asian pts. It is also important to validate the RMH score and NLR for newer phase I studies, including immunotherapy and vaccine studies. This study aims to validate the RMH score and NLR in a P1 clinical trials unit in Singapore and is the largest Asian study to date which includes novel P1 therapies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
